I
N THE DECADE BETWEEN 1956 AND 1966, investigators in Framingham, Mass, defined age, hypertension, smoking, diabetes, and hyperlipidemia as major determinants of coronary heart disease and coined the term coronary risk factors. [1] [2] [3] [4] [5] Over time, these markers were codified into global risk scores for assessment of cardiovascular risk. [6] [7] [8] However, for women, up to 20% of all coronary events occur in the absence of these major risk factors, 9 whereas many women with traditional risk factors do not experience coronary events. 10 Furthermore, over the past halfcentury, understanding of the biological processes underlying atherothrombosis has markedly shifted to encompass the complex biology of hemostasis, thrombosis, inflammation, endothelial dysfunction, and plaque instability. 11, 12 Despite this changing view of pathophysiology, variables included in current risk algorithms for women are largely unchanged from those recommended 40 years ago. Additional risk markers that have been proposed include alternative lipid measures, such as apolipoproteins A-I and B-100, non-high-density lipoprotein cholesterol (HDL-C), and lipoprotein(a); inflammatory biomarkers such as high-sensitivity C-reactive protein (hsCRP), soluble intercellular adhesion molecule 1 (sICAM-1), and fibrinogen; markers of glycemic control such as glycated hemoglobin A 1c ; and plasma creatinine and homocysteine levels. 13 However, data are scant evaluating whether improved risk prediction algorithms can be developed that use these markers. [14] [15] [16] We assayed all of these novel biomarkers as well as a large number of tradi- tional risk determinants at baseline in a cohort of 24 558 initially healthy US women who were prospectively followed up for a median 10.2 years for incident myocardial infarction, stroke, coronary revascularization, or cardiovascular death. In a random subset comprising two thirds of these women (model derivation cohort, n=16 400), we developed 2 novel algorithms for global risk prediction. We then tested the effectiveness of these new prediction models in the remaining one third of the women (test validation cohort, n=8158).
METHODS Study Participants, Laboratory Evaluation, and End Point Ascertainment
Study participants were derived from the Women's Health Study (WHS), a nationwide cohort of US women 45 years and older free of cardiovascular disease and cancer at study entry initiated in September 1992. 17 Women eligible for the current analysis were those who provided an adequate baseline plasma sample (n=27 939) and had complete ascertainment of all blood covariates of interest (n=24 558).Exposuredatawerecollected for age, race/ethnicity, diabetes, blood pressure,bloodpressuretreatment,smoking status, cholesterol treatment, menopausal status, postmenopausal hormone therapy use, height, weight, alcohol use, exercise frequency, parental history of myocardial infarction before age 60 years, and current multivitamin use. All participantsself-reportedrace/ethnicityaswhite, black, Hispanic American, Asian American, or other. All women were followed up through March 2004 for a median period of 10.2 years (interquartile range, 9.7-10.6 years) for incident myocardial infarction, ischemic stroke, coronary revascularization,andcardiovasculardeaths; these were adjudicated by an end-points committee after medical record review. Allstudyparticipantsprovidedwritteninformed consent. The study protocol was approvedbytheinstitutionalreviewboard of Brigham and Women's Hospital (Boston, Mass).
All women had baseline plasma samples, 76% of whom had fasting blood samples. The plasma samples were measured in a core laboratory facility for total cholesterol, HDL-C, low-density lipoprotein cholesterol (LDL-C), lipoprotein (a), apolipoproteins A-I and B-100, hsCRP, sICAM-1, fibrinogen, creatinine, hemoglobin A 1c , and plasma homocysteine concentration. The core laboratory is certified by the National Heart, Lung, and Blood Institute/Centers for Disease Control and Prevention Lipid Standardization Program. Assay characteristics and coefficients of variation are available upon request.
Derivation of Novel Risk Prediction Algorithms
Two thirds of the study participants (n=16 400) were randomly assigned to a model derivation data set and one third (n=8158) were reserved as an independent validation data set.
Among women allocated to the model derivation set, the best overall prediction algorithm (model A) was fit using Cox proportional hazards models. All available exposure variables and all blood biomarkers were considered for this initial model, as were all potential transformations and interactions between them. Both stepwise selection procedures and multiple additive regression trees 18 were used for variable selection, assessment for interactions, and model development. Partial dependence plots were examined for evidence of interaction, even in the absence of main effects. These interaction terms were then further tested in the Cox models.
The final criterion for inclusion in model A was minimization of the Bayes Information Criterion (BIC). 19 The BIC is a likelihood-based measure in which lower values indicate better fit and in which a penalty is paid for increasing the number of variables. Thus, the variables selected for inclusion should provide not only the best fit but also a parsimonious prediction model. The BIC is not influenced by the number of covariates, so models can be directly compared.
Once variables were selected for model A, we created a second model (model B) that was simplified for the purpose of clinical application and efficiency. For example, in these data non-HDL-C [total cholesterol −HDL-C] is highly correlated with apolipoprotein B-100 (r=0.87), and HDL-C is highly correlated with apolipoprotein A-I (r=0.80). 20 Thus, model B substituted total cholesterol and HDL-C. Simplified model B also eliminated lipoprotein(a) because prior work in this cohort has found the predictive utility of lipoprotein(a) to be limited to those with extremely high values (Ͼ90th percentile) and concomitant hyperlipidemia. 21 To allow for direct comparison, the BIC was calculated using data from the derivation cohort for models A and B, as well as for models based exclusively on covariates used in the current Adult Treatment Panel III (ATP-III) risk prediction algorithm 7 or in the Framingham Risk Score, 6 but with coefficients reestimated in the WHS data.
Testing and Validation of Novel Risk Prediction Algorithms
Once determined in final form, models A and B were prospectively tested in the validation data set of 8158 women. In this validation stage, 3 global measures were used to evaluate each prediction model: Entropy (a likelihood-based function for dichotomousoutcomesforwhichsmaller values indicate better fit); the Yates slope (the difference in predicted risk between cases and noncases for which larger values indicate better fit); and the Brier score (which computes the sum of squared differences between the observed outcome and fitted probabilities and for which smallervaluesindicatebetterconcordance between predicted and observed outcomes). 22, 23 Because all women were followed up for at least 8 years, observed status and predicted risk were evaluated and compared as of 8 years of follow-up for all measures.
In addition to these global measures, we assessed the predictive accuracy of each derived model by looking at 2 components of accuracy: discrimination and calibration. Discrimination was evaluated using the C statistic that represents the area under the receiver operating characteristic curve (for which larger values indicate bet-ter discrimination). To assess model calibration (or how closely the predicted probabilities reflect actual risk), the Hosmer-Lemeshow calibration statistic comparing observed and predicted risk was computed based on categories defined by 2% increments in predicted risk.
To compare the performance of models A and B to current risk prediction algorithms, we also computed each of these summary statistics in the test cohort using models limited exclusively to covariates defined in the current ATP-III or Framingham Risk Scores, but with coefficients reestimated in the WHS cohort. We additionally computed each of these summary statistics for predicted outcomes based on formal application of the published ATP-III and Framingham Risk scoring systems as estimated from Framingham data. 6, 7 Risk Stratification, Reclassification, and Clinical Application For ease of interpretation and to address the critical clinical issues of reclassification and risk stratification, we divided all participants in the test cohort into the 10-year risk groups of less than 5%, 5% to less than 10%, 10% to less than 20%, and 20% or higher using covariates currently included in the ATP-III risk prediction model. We then calculated the proportion of participants in the test cohort who were reclassified into either higher-or lower-risk categories using models A or B rather than the covariates in the ATP-III model and then compared observed to predicted events during the follow-up period.
Finally, to mimic clinical practice, we repeated these latter analyses using the published ATP-III risk prediction score to determine 10-year risk groups rather than the refitted model using the ATP-III covariates; because diabetes is considered acoronaryriskequivalentincurrentATP-III guidelines, this final analysis was restricted to nondiabetic study participants.
Analyses were conducted using SAS version 9.1 (SAS Institute Inc, Cary, NC), SPlus version 7.0 (Insightful Corp, Seattle, Wash), and Treenet version 2.0 (Salford Systems, San Diego, Calif).
RESULTS

TABLE 1
shows baseline characteristics and biomarker levels for women in the derivation and validation cohorts.
During follow-up, 504 cardiovascular events occurred in the derivation cohort and 262 in the validation cohort. Abbreviations: HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; sICAM-1, soluble intercellular adhesion molecule 1. SI conversion factors: to convert creatinine to µmol/L, multiply by 88.4; fibrinogen to µmol/L, multiply by 0.0294; homocysteine to mg/dL, divide by 7.397; inches to centimeters, multiply by 2.54; pounds to kilograms, multiply by 0.45; lipoprotein(a) to µmol/L, multiply by 0.0357; and total cholesterol, HDL-C, and LDL-C to mmol/L, multiply by 0.0259. *Percentages may not sum to 100 due to rounding and some numbers may not add to the total due to missing information. †Body mass index is calculated as weight in kilograms divided by height in meters squared.
Model Derivation and Development
In the model derivation cohort, 35 potential variables (and all possible interactions between them) were evaluated for model inclusion. Of these, only 9 were included in model A, the bestfitting predictive model with the smallest BIC value; age, systolic blood pressure, current smoking, apolipoprotein B-100, hsCRP, apolipoprotein A-I, parental history of myocardial infarction before age 60 years, and 2 interaction terms, hemoglobin A 1c if diabetes was present and lipoprotein(a) level if apolipoprotein B-100 was 100 mg/dL or higher. The ␤ coefficients, standard errors, and P values for each of these covariates in best-fitting model A are shown in TABLE 2.
Given selection of these 9 variables, some markers, such as homocysteine and sICAM-1, appeared to predict risk, but did not satisfy the BIC criterion for model inclusion. Other notable variables that did not further minimize the BIC once the above variables were taken into account included body mass index, alcohol use, exercise frequency, menopausal status, hormone therapy, fibrinogen, and creatinine. Table 2 also presents ␤ coefficients, standard errors, and P values for simplified model B, which was otherwise identical to model A, but substituted total and HDL-C for apolipoproteins B100 and A-I, and eliminated the interaction term requiring measurement of lipoprotein(a) if apolipoprotein B-100 was 100 mg/dL or higher.
In the derivation data set, the BIC value for model B (BIC=9067.5) was not as small as that of the best-fitting model A (BIC=9039.4), suggesting some loss of predictive ability with clinical simplification. However, model B nevertheless was associated with smaller BIC values than were models based on covariates used in the ATP-III prediction model (BIC=9098.5) or those based on covariates used in the Framingham Risk Score (BIC=9161.2). Thus, in the model derivation set, both model A and model B appeared to improve risk prediction over that achieved with currently measured covariates BOX. 
Model Testing and Validation
Reclassification and Clinical Application
Althoughformalstatisticaltestingprovides a method of evaluating model superiority, we believe the critical issue for clinicalapplicationistheproportionofpatients reclassifiedusinganewriskalgorithmand whether the magnitude of this reclassification is large enough to alter physician behavior with regard to prevention. 24 To address this issue, TABLE 4 presents the proportion of women in the validation cohort initially classified as having a 10-year risk of less than 5%, 5% to less than 10%, 10% to less than 20%, and 20% or higher based on ATP-III covariates (with coefficients reestimated in the WHS data) who would be reclassified to higher-or lower-risk categories by model A and model B. As shown for model A, the proportion of women reclassified was small for those with a 10-year risk of less than 5% (2.5%). However, 43% of all women estimated to be at 5% to less 10% risk or at 10% to less than 20% risk using ATP-III covariates were reclassified to higher or lower clinical risk categories when model A was used instead. with predicted rates in nearly all groups; of the 681 participants reclassified by model A, all but 93 were placed into more accurate risk categories. TABLE 5 presents similar analyses for women who did not have diabetes with direct application of the published ATP-III risk score. As shown, about 50% of all women with an estimated 10-year risk for coronary heart disease of 5% to less than 10% or 10% to less than 20% according to ATP-III were reclassified to higher or lower risk categories when model A was used instead. Again, there was excellent matching of actual and predicted rates for model A; of the 722 participants without diabetes who were reclassified by model A, all but 2 were placed into more accurate risk categories.
As also presented in Table 4 and Table 5 , similar effects were achieved for clinically simplified model B limited to age, systolic blood pressure, hemoglobin A 1c if diabetic, current smoking, total and HDL-C, hsCRP, and parental history of myocardial infarction before age 60 years. Although the proportion of individuals at intermediate-risk reclassified by model B (30%-45%) was smaller than that of model A (43%-50%), there was still excellent matching of actual to predicted event rates in nearly all groups. For example, of the 647 participants without diabetes in Table 5 who were reclassified by model B, all but 6 were placed into more accurate risk categories. Neither new algorithm added substantive information for women at very low initial risk (Ͻ5% 10-year risk based on published ATP-III risk scores).
Examples for Outpatient Clinical Practice: The Reynolds Risk Score
As a practical example, TABLE 6 provides estimated 10-year risks based on variables in our most parsimonious model (model B, the Reynolds Risk Score) for a 50-year-old women smoker without diabetes with an ATP-III estimated risk of 11.5%. As shown, 10-year risk estimates based on model B range from a low of 4.9% to a high of 18.4% for this hypothetical patient.
With regard to reclassification, as shown in the FIGURE for a representative population of 100 000 US women without diabetes at intermediate risk (80 000 at 5% to less than 10% and 20 000 at 10% to less than 20% 10-year risk by ATP-III), use of the clinically simplified Reynolds Risk Score would place 13 500 of these women at low risk, 48 500 at low to moderate risk, 32 500 at moderate to high risk, and 5400 at high risk.
COMMENT
In this study of 24 558 initially healthy US women followed up for a median of 10.2 years, we developed and validated risk prediction algorithms that reclassified 40% to 50% of women currently predicted to be at intermediate risk into higher-or lower-risk categories and did so with greatly improved accuracy when compared with models based on current ATP-III prediction scores. This effect was present not only for our best-fitting model (model A) but also for a simplified clinical model limited to age, systolic blood pressure, hemoglobin A 1c if diabetic, current smoking, total and HDL-C, hsCRP, and parental history of myocardial infarction before age 60 years (model B, the Reynolds Risk Score).
In addition to providing opportunity for improved risk stratification, we believe these data have clinical implications for the targeting of preventive therapies. In these analyses, large proportions of women with 10-year risk estimates of 5% to less than 10% or of 10% to less than 20% based on current ATP-III risk scores were reclassified at either higher or lower risk of total cardiovascular disease when either of the new algorithms was used. In current US treatment guidelines that take into account the benefits, risk, and cost of lipidlowering therapy, statins are considered an option for those with 10-year risk estimates of 10% or greater 25 ; a more conservative approach taken in Europe typically limits statin therapy to those with 10-year risks of 20% or more. 8 In both settings, application of the models described herein should allow more accurate targeting of statin prescriptions to those patients with the most appropriate level of risk so as to minimize toxicity and maximize benefit and cost efficacy.
We also believe these data provide optimism regarding novel cardiovascular risk factors. In our best-fitting model, hemoglobin A 1c , hsCRP, lipoprotein(a), apolipoproteins A-I and B-100, and parental history were included because each contributed to minimization of the BIC. However, homocysteine, fibrinogen, sICAM-1, and creatinine were not included in our par- simonious models despite univariate risk associations. Similarly, neither body mass index nor exercise frequency added further prognostic information on overall global risk. 26, 27 By contrast, we observed that glucose control as evaluated by hemoglobin A 1c was an effective biomarker in these women that modified the risk associated with diabetes.
Our findings might appear to conflict with a recent report from the Framingham Heart Study in which only marginal utility for novel risk factors was described. 16 However,insteadofseekingevidence of reclassification, that analysis relied solely on the C statistic, a technique known to have limited utility for evaluatingpredictionmodelsforwhichthetask istoassessfutureriskinacurrentlyhealthy population. 28 Equally important, that analysis relied on data from 1712 women who experienced only 68 vascular events,manyofwhichwerecodedasheart failure or coronary insufficiency. By contrast, the risk algorithms described herein rely on data from 24 558 women who experienced 766 hard cardiovascular end points. We also note that in a separate Framingham Heart Study analysis addressing the additive value of hsCRP, use of this biomarker alone reclassified 25% of those with ATP-III risks between 5% and 20%, data fully consistent with those presented herein. 29 Despite advantages of sample size and power, limitations of our analysis merit discussion.First,becauseourdataarelimited to women and our cohort is largely white with a relatively narrow socioeconomic range, care should be taken before generalizing to other populations. We note, however, that all components of models A and B have previously been found to predict cardiovascular risk in men [30] [31] [32] [33] [34] and that both hsCRP and parental history of vascular disease have previously been shown to predict risk within the Framingham cohort itself. 29, 35, 36 Second, our data on blood pressure, obesity, and family history were based on self-report. However, the WHS is composed of female health professionals who are known to provide accurate reports of lifestyle factors and health status, including blood pressure and weight. 37, 38 In addition, self-reported blood pressure, body mass index, and family history have previously been shown in the WHS to be strong predictors of cardiovascular risk, with odds ratios consistent in magnitude with those observed in other major studies. [39] [40] [41] Regarding parental history, we used a conservative cut point of age younger than 60 years to be consistent with prior findings in this cohort and in recent analyses from Framingham. 41, 42 The inclusion of family history in these algorithms underscores the importance of genetic influences on risk among women; in a recent study of women with low Framingham risk who had premature coronary disease in a first-degree relative, nearly a third had significant subclinical atherosclerosis and 17% had atherosclerotic burden exceeding the 90th percentile. 43 Third, following recent recommendations, 44 we elected in our analysis to use a combined end point of myocardial infarction, ischemic stroke, coronary revascularization, and cardiovascular mortality.Webelievethisisanappropriatechoice because this end point has typically been usedinmajorcardiovascularclinicaltrials evaluating interventions for primary prevention, including recent trials of aspirin and statin therapy.
Finally, we limited our analysis to blood-based biomarkers and traditional epidemiological risk factors, in part to ensure a cost-effective approach for primary prevention that could be directly compared with the ATP-III algorithm. These data thus do not examine the potential for atherosclerotic imaging tests to serve as an alternative method for evaluating risk. However, we believe the methods developed herein-variable selection in a derivation data set to minimize the BIC followed by prospective testing in a second validation cohortshould provide a structure for the formal evaluation of emerging risk predictors, including potential imaging tests.
As 8 to 10 million US women have an ATP-III estimated 10-year risk between 5% and 20%, application of these data could have an immediate effect on cardiovascular prevention. 45 A userfriendly calculator for the Reynolds Risk Score can be freely accessed at http: //www.reynoldsriskscore.org.
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